1. Oral Treatment Strategies in CLL

3. Agenda

4. First-Line Treatment of CLL

5. Phase 3 iLLUMINATE Study Ibrutinib + Obinutuzumab vs Chlorambucil + Obinutuzumab

6. Ibrutinib Alone or in Combination With Rituximab vs Bendamustine + Rituximab

7. Ibrutinib + Rituxumab vs FCR

8. iFCG for First-Line Treatment of CLL Study Design

9. iFCG for First-Line Treatment of CLL Study Results

10. Phase 2 Study of Ibrutinib + Venetoclax in High-Risk Patients

11. PCYC-1102 Phase 1b/2 Study 7 Years of Follow-Up of Single-Agent Ibrutinib

12. ACE-CL-001: Phase 1/2 Study of Acalabrutinib

13. Relapsed/Refractory CLL

14. Durability of Responses After Drug Cessation of Venetoclax and Rituximab

15. Phase 3 MURANO Study of VenR vs BR Long-Term Follow-Up

16. Phase 3 MURANO Study Analysis of PB MRD

17. Genetic Mutations Associated With Resistance to Venetoclax and Ibrutinib

18. CLARITY Study of Ibrutinib + Venetoclax PB and BM MRD

19. Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in CLL

20. Durable Remissions after Treatment Discontinuation in CLL With del(17p)/TP53 Mutations

21. JCAR017

22. Anti-CD19 CAR T Cells in Combination With Ibrutinib for the Treatment of CLL

23. Phase 2 Study of Nivolumab + Ibrutinib in RT

24. CLL14 Study Design

25. Concluding Remarks

26. Abbreviations

27. Abbreviations (cont)

28. Abbreviations (cont)